Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: Primary care

Trials Find Potential Treatments for SLE, Lupus Nephritis

Michele B. Kaufman, PharmD, BCGP  |  May 31, 2025

In summer 2024, two phase 3 studies were released with promising findings for the treatment of patients with systemic lupus erythematosus (SLE) and those with lupus nephritis. SLE Disease Activity Dapirolizumab pegol is a novel, investigational, Fc-free anti-CD40L agent for people living with moderate to severe SLE.1 The randomized, double-blind, parallel-group PHOENYCS GO trial (N=321)…

Filed under:ConditionsDrug UpdatesSystemic Lupus Erythematosus Tagged with:dapirolizumab pegolLupus nephritis supplementobinutuzumab

Case Report: Lupus Nephritis, or a Mimic?

Matthew J. Mandell, DO, FACP, Yishui Chen, MD, Prerna Rastogi, MD, PhD, & Rebecca Tuetken, MD, PhD  |  May 31, 2025

Syphilis, an ancient disease caused by the spirochete Treponema pallidum, has been historically referred to as the great mimicker given its heterogenous presentation. Both systemic lupus erythematosus (SLE) and syphilis can have multi-systemic involvement. Both parvovirus B19 and syphilis have been reported to cause histologic features similar to those seen in lupus nephritis. We present…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:case reportLupus nephritis supplementparvovirus B19syphilis

Ethical Concerns in Rheumatology Require Nuance

Vanessa Caceres  |  May 26, 2025

Patient autonomy in healthcare decisions and physician conflicts of interest are just two areas of ethical concerns that arise frequently in rheumatology. Dr. Kelly Weselman discusses ethical dilemmas and how to address them.

Filed under:CareerEducation & TrainingEthicsGuidance Tagged with:Access to careConflict of interestEthicspatient care

How to Recognize Inborn Errors of Immunity

Vanessa Caceres  |  May 13, 2025

Inborn errors of immunity may not always be easy to recognize, but rheumatologists should look out for them. Dr. Bharat Kumar shares his insights.

Filed under:ConditionsOther Rheumatic Conditions Tagged with:ACR on Airimmune deficiencyinborn errors of immunitypatient carepodcast

Abatacept Shows Promise for Some Myositis Patients

Deborah Levenson  |  May 12, 2025

Injected abatacept may be a worthwhile treatment for certain patients with idiopathic inflammatory myositis (IIM), according to recent research.1 Patients with the rare autoimmune conditions involving inflammation of muscle (myositis) and other organ systems suffer widespread organ dysfunction, increased morbidity, physical disabilities and early death. Symptoms vary by subtype. For example, dermatomyositis (DM) involves muscle…

Filed under:Biologics/DMARDsConditionsDrug UpdatesMyositisResearch Rheum Tagged with:abataceptAC&Ridiopathic inflammatory myositis

Carol A. Langford, MD, MHS

President’s Corner: How to Stay on Top of ACR/ARP News

Carol A. Langford, MD, MHS  |  May 12, 2025

When speaking to ACR and ARP members, people are always interested in hearing about the most recent news coming out of the ACR, specifically in areas of interest to them and their patients. It was these discussions that prompted me to make enhancing connections and communications between the ACR and its members one of my…

Filed under:From the CollegePresident's Perspective Tagged with:communicationsPresident's Corner

Can Stem Cell Transplantation Improve Survival Rates in Patients with Systemic Sclerosis?

Arthritis & Rheumatology  |  April 30, 2025

Autologous hematopoietic stem cell transplantation (AHSCT) may improve the survival rate of patients with diffuse cutaneous systemic sclerosis (SSc), according to Georges et al. The single-arm clinical trial demonstrated the effectiveness of AHSCT and maintenance therapy. Researchers also identified potential risk factor of AHSCT in patients with low eGFR before transplantation.

Filed under:ConditionsSystemic Sclerosis Tagged with:autologous hematopoietic stem cell transplantation (AHSCT)diffuse cutaneous systemic sclerosisSScstem cell transplantationsystemic sclerosis (SSc)

Rheumatology Research Workshop attendees discuss an abstract poster at the poster session and reception.

A Passion for Research

Deborah Levenson with ACR staff  |  March 24, 2025

With three new endowments established, the ACR Rheumatology Research Foundation aims to support and inspire the future of rheumatology and the innovative research that will one day benefit patients.

Filed under:AwardsCareerEducation & TrainingProfessional TopicsProfiles Tagged with:RosenbaumTsokos

Editor's Pick

Cannabis for Pain Management in Rheumatology

Joanna Zeiger, PhD, & Kaleb Michaud, PhD  |  March 7, 2025

‘Cannabis has a long history of being used for pain management,’ says Physician Editor Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS. ‘What does it mean for rheumatology patients moving forward? Read our article for one answer to this question.’ As cannabis becomes more widely legalized, both in the U.S. and internationally, its use for pain…

Filed under:ConditionsDrug UpdatesPain SyndromesPatient Perspective Tagged with:Editor's PickJoanna ZeigerKaleb MichaudPhD

Potential Biologic Drug Treatment for IgG4-RD Identified

Deborah Levenson  |  March 6, 2025

Inebilizumab reduces the risk of immunoglobulin G4-related disease (IgG4-RD) flares and increases the likelihood of flare-free, complete remission at one year, a recent study shows.1 The randomized, doubleblind, placebo-controlled MITIGATE trial showed that inebilizumab reduced the risk of IgG4-RD symptoms by 87%, compared with placebo. About IgG4-RD IgG4-RD is chronic, rare condition that has, so…

Filed under:Drug UpdatesResearch Rheum Tagged with:B cell depletionIgG4-RDinebilizumab

  • « Previous Page
  • 1
  • …
  • 63
  • 64
  • 65
  • 66
  • 67
  • …
  • 137
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences